Beckie Fenrick, PharmD, MDA, Senior Director, Medical Operations, Care Models and Affordability Solutions, Florida Blue, says that the trending increase in companion diagnostics allows for more personalized medicine.
Beckie Fenrick, PharmD, MBA, Senior Director, Medical Operations, Care Models and Affordability Solutions, Florida Blue, says that the trending increase in companion diagnostics allows for more personalized medicine. She adds that the diagnostics can identify the appropriateness of treatments for specific beneficiaries.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More